Habib Ramdani - Virbac SA Deputy CFO

VIRP Stock  EUR 324.00  0.50  0.15%   

Insider

Habib Ramdani is Deputy CFO of Virbac SA
Age 46
Phone33 4 92 08 71 00
Webhttps://corporate.virbac.com

Virbac SA Management Efficiency

The company has return on total asset (ROA) of 0.091 % which means that it generated a profit of $0.091 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1542 %, meaning that it generated $0.1542 on every $100 dollars invested by stockholders. Virbac SA's management efficiency ratios could be used to measure how well Virbac SA manages its routine affairs as well as how well it operates its assets and liabilities.
Virbac SA has accumulated 13.15 M in total debt with debt to equity ratio (D/E) of 98.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Virbac SA has a current ratio of 1.21, suggesting that it may not have the ability to pay its financial obligations in time and when they become due. Debt can assist Virbac SA until it has trouble settling it off, either with new capital or with free cash flow. So, Virbac SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Virbac SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Virbac to invest in growth at high rates of return. When we think about Virbac SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Sylvain MorgeauBiomerieux SA
N/A
Paolo BicciTrigano SA
65
Gwenan WhiteIpsen SA
N/A
MarieHlne FeuilletTrigano SA
74
Guillaume BouhoursBiomerieux SA
47
Franois FeuilletTrigano SA
74
Steven HildemannIpsen SA
N/A
Yan MDIpsen SA
56
Heiko ImhlSartorius Stedim Biotech
N/A
Frederic BesemeBiomerieux SA
67
Michel FreicheTrigano SA
62
Franois LacosteBiomerieux SA
N/A
Mark MillerBiomerieux SA
N/A
Yasha MitrottiBiomerieux SA
N/A
Philippe GruetVetoquinol
N/A
John MackaySartorius Stedim Biotech
61
Olivier GuitardSartorius Stedim Biotech
N/A
Stephan GagneIpsen SA
N/A
Piet WigerinckIpsen SA
54
Craig MarksIpsen SA
N/A
Petra KirchhoffSartorius Stedim Biotech
54
Virbac SA produces and sells medicines and vaccines for companion and food-producing animals. Virbac SA was founded in 1968 and is headquartered in Carros, France. VIRBAC operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. It employs 4893 people. Virbac SA (VIRP) is traded on Euronext Paris in France and employs 5,120 people.

Management Performance

Virbac SA Leadership Team

Elected by the shareholders, the Virbac SA's board of directors comprises two types of representatives: Virbac SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Virbac. The board's role is to monitor Virbac SA's management team and ensure that shareholders' interests are well served. Virbac SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Virbac SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Nathalie Pollet, Head Devel
Marc Bistuer, Head CEO
Sandrine Brunel, Head Communications
Bertrand Havrileck, Biologicals RD
Sebastien Huron, Chairman Board
Habib Ramdani, Deputy CFO
Manuela Rodrguez, Director Projects
Christian Karst, GM Devel
Francesca Cortella, Head HR
Sophie Favini, Head Operations

Virbac Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Virbac SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Virbac Stock

Virbac SA financial ratios help investors to determine whether Virbac Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Virbac with respect to the benefits of owning Virbac SA security.